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Crohn’s disease (CD) results from dysregulated immune responses to gut microbiota in genetically susceptible individuals, aﬀecting
multiple areas of the gastrointestinal tract. Innate lymphoid cells (ILCs) are tissue-resident innate eﬀector lymphocytes which play
crucial roles in mucosal immune defense, tissue repair, and maintenance of homeostasis. The accumulation of IFN-γ-producing
ILC1s and increased level of proinﬂammatory cytokines produced by ILCs has been observed in the inﬂamed terminal ileum of
CD patients. To date, the precise mechanisms of ILC plasticity and gene regulatory pathways in ILCs remain unclear. Signal
transducer and activator of transcription 3 (STAT3) regulates gene expression in a cell-speciﬁc, cytokine-dependent manner,
involving multiple immune responses. This study proposes the positive correlation between the prevalence of STAT3 rs744166
risky allele “A” with the severity of disease in a cohort of 94 CD patients. In addition, the results suggest an increased STAT3
activity in the inﬂamed ileum of CD patients, compared to unaﬀected ileum sections. Notably, IL-23 triggers the diﬀerentiation
of CD117+NKp44- ILC3s and induces the activation of STAT3 in both CD117+NKp44- and CD117-NKp44- ILC subsets,
implying the involvement of STAT3 in the initiation of ILC plasticity. Moreover, carriage of STAT3 “A” risk allele
exhibited a higher basal level of STAT3 tyrosine phosphorylation, and an increased IL-23 triggered the pSTAT3 level. We
also demonstrated that there was no delayed dephosphorylation of STAT3 in ILCs of both A/A and G/G donors. Overall,
the results of this study suggest that IL-23-induced activation of STAT3 in the CD117-NKp44- ILC1s involves in ILC1-toILC3 plasticity and a potential regulatory role of ILC1 function. Those genetically susceptible individuals carried STAT3
rs744166 risky allele appear to have higher basal and cytokine-stimulated activation of STAT3 signal, leading to prolonged
inﬂammation and chronic relapse.

1. Introduction
Crohn’s disease (CD) is one type of inﬂammatory bowel
disease (IBD) that involves a chronic relapsing inﬂammation
of the gastrointestinal tract, causing abdominal pain and
diarrhea and can eventually lead to severe strictures or ﬁstulae which enhance the need for surgical intervention [1]. The
pathogenesis of CD involves a complex interaction between
genetic factors, environmental factors, and dysregulated
immune responses [2]. To date, the precise mechanisms

behind the disease initiation and progression remain unclear.
However, it is widely accepted that CD involves an inappropriate and continuing mucosal inﬂammatory immune
response to intestinal microﬂora in genetically susceptible
individuals [3, 4]. Historically, the dysfunctional adaptive
immune responses were investigated in terms of Th1/Th17
responses in CD patients, and results suggested that T cells
are responsible for the increased production of proinﬂammatory cytokines, such as IFN-γ and IL-17A [5]. Recently,
increasing evidence suggests that innate immunity also plays
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a signiﬁcant role in the pathogenesis of CD [6, 7]. Innate lymphoid cells (ILCs) have been identiﬁed as innate eﬀector cells
that are involved in bacterial defense, induction of inﬂammation, and the maintenance of homeostasis [8]. The nomenclature of ILCs is based on their signature cytokines and the
transcriptional factors that regulate their diﬀerentiation.
They are classiﬁed into natural killer (NK) cells, group 1 ILCs
(ILC1s), group 2 ILCs (ILC2s), group 3 ILCs (ILC3s), and
lymphoid tissue inducer (LTi) cells [9]. In contrast to T cells,
ILCs lack antigen-speciﬁc receptors and are constitutively
located in barrier tissues, responding to alarmins as well as
cytokine signals released following tissue damage or mucosal
infection [10, 11]. As tissue-resident innate compartments of
T helper cells, ILCs undergo transdiﬀerentiation, also known
as plasticity, in response to cytokine cues in the surrounding
tissue microenvironment [12]. Speciﬁcally, in Crohn’s
disease patients, we and other researchers have identiﬁed
the accumulation of IFN-γ-producing ILC1s at the expense
of IL-17/IL-22-producing ILC3s in the inﬂamed intestinal
tissues of Crohn’s disease patients, implying this ILC3-toILC1 plasticity may be involved in the CD pathogenesis
[13, 14]. Moreover, researchers have identiﬁed that the diﬀerentiation toward ILC1s was driven by IL-12, and conversely,
IL-23 promoted polarization toward ILC3s in vitro and
in vivo [15]. Notably, IL-23 responsive ILCs have been
recently recognized as the important cell population that
associates with the pathogenesis of colitis in several murine
models [16].
Genome-wide association studies (GWAS) have identiﬁed 170 disease susceptibility gene loci that are associated
with Crohn’s disease [17]. In 2014, a meta-analysis indicated
that the STAT3 rs744166 polymorphism was highly associated with CD susceptibility, especially among Caucasians
[18]. Additionally, the STAT3 rs744166 risk allele “A” has
been associated with increased cellular STAT3 activation in
leukocytes in pediatric Crohn’s disease patients [19]. Signal
transducer and activator of transcription 3 (STAT3) is a crucial transcription factor which regulates cells associated with
both innate and adaptive mucosal immunity in a cell-speciﬁc,
cytokine-dependent manner [20]. Particularly, STAT3 plays
a central role in Th17 commitment through its direct regulation of RORγt and regulates Th17-cytokine production in
response to IL-23 [21]. In addition, it has been shown that
STAT3 is essential for ILC3s to produce IL-22 against intestinal infection in mice [22, 23]. Recent improvements in
genetic analysis in human studies have revealed the distinct
gene regulatory mechanisms in adaptive and innate lymphoid cells [24, 25]. Although ILC3s are the innate analog
of Th17 cells, the exact regulation of STAT3 in ILC3 development and plasticity remains unclear. In this study, we investigate the role of STAT3 in the pathogenesis and progression
of Crohn’s disease, and more speciﬁcally, we examine the
STAT3 signaling involving in innate lymphoid cell plasticity.

2. Materials and Methods
2.1. Human Intestinal Lamina Propria Mononuclear Cell
(LPMC) Isolation. All the surgical resections of the terminal
ileum from Crohn’s disease patients were obtained from
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Table 1: STAT3 rs744166 genotyping in a cohort of Crohn’s disease
patients.
Genotype
GG
GA
AA

Number

Frequency

12
41
41

12.8%
43.6%
43.6%

UF Health Shands Hospital, following an approved
IRB#201500440. LPMCs were isolated by epithelial elimination and enzyme digestion. Brieﬂy, the surgical resections were cut into 1-2 mm pieces after removal of the
outer fat tissue and muscle layer. The epithelial layer was
removed by 1X Hanks’ Balanced Salt Solution (HBSS)
with phenol red and glucose, no calcium, and no magnesium, containing 2% FBS (Gibco®), 100 U/ml penicillin,
100 μg/ml streptomycin, 25 μg/ml gentamycin, and 0.5
mM DTT. Tissues were then digested with 1X HBSS containing 1% FBS (Gibco®), 100 U/ml collagenase XI
(Roche), 20 μg/ml Dispase neutral protease II (Roche),
and 10 μg/ml deoxyribonuclease I (StemCell Technologies). The remaining tissues were mechanically dissociated
and were passed through 70 μm cell strainers (Corning®).
All cells were then slowly cryopreserved in CryoStor®
CS10 (StemCell Technologies) and transferred into liquid
nitrogen for future use.
2.2. Human Peripheral Blood Mononuclear Cell (PBMC)
Isolation. Donor blood was purchased from LifeSouth
Community Blood Center, and patient blood was obtained
from UF Health Shands Hospital, following an approved
IRB#201500440. PBMCs were isolated by gradient centrifugation. Brieﬂy, whole blood samples were diluted 1 : 1 ratio
with 1XPBS containing 2% FBS. Diluted blood samples were
carefully transferred into SepMate™-50 tubes containing 15
ml of Lymphoprep™ (StemCell Technologies). Samples were
then centrifuged at 1,200xg for 10 mins, and the cell suspensions above the insert in SepMate™-50 tubes were transferred
into new 50 ml conical tubes. PBMCs were collected by
centrifuging at 300xg for 8 mins. All cells were then slowly
cryopreserved in CryoStor® CS10 (StemCell Technologies)
and transferred into liquid nitrogen for future use.
2.3. Genotyping of STAT3 rs744166. Genomic DNA was
extracted from whole blood using the Gentra Puregene Kit
(QIAGEN). Patients were genotyped for the STAT3
rs744166 (assay ID: C___3140282_10, Cat. No. 4351379,
TaqMan) single nucleotide polymorphism (SNP) using the
TaqMan system, running on the QuantStudio 7 Flex RealTime PCR System (Applied Biosystems).
2.4. Quantitative RT-PCR. Total RNA was isolated from
intestinal tissues of Crohn’s disease patients using QIAzol
Lysis Reagent (QIAGEN) or from whole blood of CD
patients using the RNeasy Kit (QIAGEN). A two-step RTPCR was performed using the SuperScript® VILO cDNA
Synthesis Kit (Thermo Fisher Scientiﬁc) for reverse transcription (RT), and PCR was done using the QuantStudio 7
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Table 2: Surgery numbers in risky allele carrier and nonrisky allele carrier among the cohort of Crohn’s disease patients.
Genotype

0

1

2

Surgery numbers
3

4

5

6

Total

GG

Number
Percentage

9
9.57%

3
3.19%

0
0%

0
0%

0
0%

0
0%

0
0%

12
12.77%

AA+GA

Number
Percentage

26
27.66%

21
22.34%

11
11.70%

9
9.57%

8
8.57%

6
6.38%

1
1.06%

82
87.23%

Total

Number
Percentage

35
37.23%

24
25.53%

11
11.70%

9
9.57%

8
8.51%

6
6.38%

1
1.06%

94
100%

Flex Real-Time PCR System (Applied Biosystems). The PCR
was performed using a 20 μl reaction volume containing the
cDNA, 2× TaqMan® Gene Expression Master Mix, nucleasefree water, and 1× TaqMan Gene Expression Assay for
STAT3 (Thermo Fisher Scientiﬁc). The housekeeping gene
GAPDH was used as an endogenous control to normalize
target gene expression levels. 2^-ΔΔCt value was calculated
and used to represent the gene expression fold change.
2.5. Immunohistochemistry. The immunohistochemistry
staining followed the manufacturer’s protocols, and the
heat-induced epitope retrieval method with citrate buﬀer
was used for antigen retrieval. Primary antibodies, speciﬁcally anti-STAT3 (Y705) antibody (rabbit polyclonal,
ab214465 (dilution 1:500), Abcam), were added and incubated at 4°C overnight. The primary antibodies were detected
using a mouse and rabbit speciﬁc HRP/DAB IHC detection
kit (ab236466, Abcam) following the manufacturer’s
instructions.
2.6. Flow Cytometry. Single-cell suspensions isolated from
intestinal tissues of CD patients were stained with FITCconjugated anti-human lineage cocktail 3 (Lin3) (CD3,
CD14, CD19, and CD20; clone: MφP9, L27, SK7, and
SJ25C1; BD Biosciences), PerCP-conjugated anti-human
CD45 (clone: HI30, BioLegend), APC-conjugated antihuman CD127 (clone: A019D5, BioLegend), PE-conjugated
anti-human NKp44 (clone: P44-8, BioLegend), PE-Cy7conjugated anti-human CD117 (clone: 104D2, eBioscience),
Brilliant Violet 421-conjugated anti-human CRTH2 (clone:
BM16, BioLegend), and Alexa Fluor 647-conjugated antiSTAT3 Phospho-Tyr705 (clone: 13A3-1, BioLegend). Viability was assessed by Fixable Yellow Dead Cell Stain (Thermo
Fisher Scientiﬁc). For phosphoﬂow staining, cells were stimulated with 20 ng/ml of recombinant human IL-23 (carrier
free, R&D) for 15 mins and were permeabilized by TruePhos™ Perm Buﬀer (BioLegend) following the manufacturer’s protocol. AbC™ Total Antibody Compensation Beads
(Cat. No. A10497, Life Technologies) and ArC™ Amine
Reactive Compensation Beads (Cat. No. A10346, Life Technologies) were used for compensation. Data were acquired
on an LSRFortessa™ ﬂow cytometer (BD Biosciences) using
BD FACSDiva™ software in the Cytometry Core at the University of Florida and analyzed by FlowJo software (Version
10, Tree Star Inc.).

2.7. Histology. The surgical tissues containing the structures
of mucosa, submucosa, and muscular layer were ﬁxed in
10% neutral-buﬀered formalin (Fisher Scientiﬁc) for at least
18 hrs. The ﬁxed tissues were then embedded in paraﬃn, sectioned, and stained with hematoxylin and eosin.
2.8. Gene Expression Heatmap. Total RNA was isolated from
intestinal tissues of Crohn’s disease patients using QIAzol
Lysis Reagent (QIAGEN), and a two-step RT-PCR was performed using the SuperScript® VILO cDNA Synthesis Kit
(Thermo Fisher Scientiﬁc) for reverse transcription (RT).
Quantitative RT-PCR was done using TaqMan® Gene
Expression Array Plates (96-well Standard Human Immune
Response Array, Cat. No. 4414073, TaqMan) on the QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems).
The expression levels of each gene were calculated using the
2^-ΔΔCt value, and GAPDH was used as endogenous control gene whereas normal unaﬀected tissue sample was used
as reference control. Heatmap of RT-PCR data was generated
using R programming.
2.9. Statistical Analysis. The correlation of surgery number
and STAT3 rs744166 risk allele was tested by a GENMOD
procedure in SAS with the adjustment of age at diagnosis.
Statistical analysis was performed using GraphPad Prism 6
software (GraphPad Software, CA), and all comparisons
between experimental groups were evaluated by the unpaired
Mann-Whitney t test. Diﬀerences with a value of p < 0 05
were considered as signiﬁcant and were indicated by an
asterisk.

3. Results
3.1. STAT3 rs744166 Risk Allele “A” Carriage Positively
Correlates with Clinical Outcomes of Crohn’s Disease
Patients. Surgery is not commonly required for CD patients;
however, depending on disease severity and chronic
relapse of inﬂammation, surgical removal of the inﬂamed
tissues is needed in certain cases. Even though the carriage
of STAT3 rs744166 risk “A” allele is relatively high in
healthy individuals, which is 56.4% compared to 63.6%
carriage in CD patients [26], it has been indicated in several studies that STAT3 rs744166 is associated with
Crohn’s disease susceptibility [18, 27]. Herein, we ﬁrst
genotyped our cohort of 94 CD patients and found that
87.2% of this cohort carried STAT3 rs744166 risk allele
“A,” heterozygous or homozygous (Table 1). In order to
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Location of stricture

Location of fistula

Total = 94

Total = 94

5.32% anal
8.51% colon
1.06% duodenum
1.06% ileocecal
35.11% ileum

1.06% ileum+anus
2.13% ileum+colon
2.13% ileum+jejunum
1.06% jejunum
42.55% none

1.06% anal
1.06% colon
1.06% colovaginal
2.13% duodenal+colon
8.51% ileum
1.06% ileum+colon
1.06% ileum+rectum
1.06% ileum+rectum+perianal

(a)

14.89% perianal
1.06% perianal+ileum
2.13% perianal+ileum+colon
4.26% perianal+rectum
1.06% perirectal
6.38% rectum
2.13% rectum+perianal
51.06% none

(b)

Composition of surgery numbers

p = 0.018
1.0
0.8
0.6
0.4
0.2
0.0
AA+GA

GG

rs744166 genotype
6
5
4
3

2
1
0
(c)

Figure 1: STAT3 rs744166 risky allele “A” positively correlates with surgery numbers in Crohn’s disease patients. Patients in this study suﬀered
stricture and ﬁstula at various sites of the gastrointestinal tract. The locations of strictures was shown in (a), and (b) demonstrated various
locations of ﬁstula in this cohort of patients. (c) The correlation of surgery numbers and carriage of risky allele “A” was tested by a
GENMOD procedure in SAS with the adjustment of age of diagnosis. Diﬀerent surgery numbers were represented as diﬀerent colors.

investigate whether this STAT3 single nucleotide polymorphism (SNP) was associated with clinical outcomes (Supplementary Table 1), we used the number of surgeries
that these patients received after diagnosis to represent
disease severity (Table 2). We observed that more than
60% of patients do not respond well to drug treatment
and eventually need surgery. Moreover, 37.22% of patients
have received multiple surgeries (surgery numbers ≥2). In
addition, 57.45% of patients have strictures located in various sites, and 48.94% of patients suﬀered from ﬁstula at

diﬀerent locations (Figures 1(a) and 1(b)). However, there
is no correlation between STAT3 rs744166 and the presence of stricture or ﬁstula. Furthermore, a statistical correlation test of numbers of surgeries and the SNP was
performed, and we found that there was a positive correlation between STAT3 rs744166 risky allele carriage (G/A
or A/A) and surgery numbers (Figure 1(c)). Taken
together, these results implied a potential involvement of
dysfunctional STAT3 activity in the chronic relapse of
Crohn’s disease patients.
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2.5

Fold change

2.0
1.5
1.0
0.5

Unaffected ileum

0.0

Inflamed ileum

(b)

(a)
SYK
PF4
NFATC4
NFATC3
MIF
LY96
LIF
EDN1
AGTR1
CD34
VEGFA
ACE
LTA
TNF
C3
FN1
SKI
SMAD7
SMAD3
TGFB1
FASLG
FAS
GNLY
GZMB
PRF1
IFNG
CYP7A1
LRP2
PTGS2
HMOX1
SELE
SELP
ICAM1
BAX
BCL2L1
BCL2
NOS2
ICOS
TNFRSF18
TBX21
HLA-DRA
CD40LG
CTLA4
CD86
CD80
CD88
PTPRC
CD40
CD38
CD28
IL2RA
CD19
CD8A
CD4
CD3E
IKBKB
NFKB2
STAT3
CSF3
CSF2
CSF1
CXCL11
CXCL10
CXCR3
CCR7
CCR5
CCR4
CCR2
CCL5
CCL2
CCL19
CCL3
IL18
IL17A
IL15
IL13
IL12B
IL12A
IL10
IL8
IL7
IL6
IL2
IL1B
IL1A

1

2
Unaffected ileum

3

4

Inflamed ileum

Unaffected ileum

5

6

SELP
LTA
LIF
SKI
TGFB1
SMAD3
BCL2
BCL2L1
FAS
PTPRC
CD38
CTLA4
CD28
ICAM1
ICOS
CCR4
CCR7
IL12B
IL2RA
CSF1
IL10
TNF
IL17A

1

3

4

5

6

Inflamed ileum

Color key
4

Inflamed ileum

2

Unaffected ileum

3

2

1
0 –1
Relative scale

–2

–3

–4

(c)

Figure 2: Increased STAT3 target gene expression and stat3 mRNA expression in the inﬂamed ileum of Crohn’s disease patients. (a)
Representative H&E staining illustrates histological appearance in unaﬀected and inﬂamed terminal ileum of CD patients. Compared
to unaﬀected ileum, the inﬂamed ileum showed distinct histological signs of inﬂammation, including increased inﬁltration of
immune cells in the lamina propria, loss of intact small intestinal architecture, and ulceration. Images were obtained under 20x
magniﬁcation. Scale bar = 50 μm. (b) stat3 mRNA expression was upregulated in the inﬂamed ileum of CD patients (n = 10), compared to
unaﬀected ileum tissues (n = 5). The gene expression fold change was calculated as 2^-ΔΔCt value, using GAPDH as endogenous control.
Statistical analysis was done by the unpaired Mann-Whitney t test, α = 0 05. (c) Altered expression pattern of inﬂammatory genes in the
inﬂamed tissues of CD patients. Among these genes, an increased STAT3-related gene expression was observed in the inﬂamed ileum of
CD patients. GAPDH was used as endogenous control.

3.2. Increased stat3 and Its Target Gene Expression in the
Inﬂamed Ileum of Crohn’s Disease Patients. To further investigate STAT3 activity in the disease state, we evaluated stat3
mRNA levels in the inﬂamed ileum tissues from CD patients
who received more than 2 surgeries. Based on distinct histological features, for instance, ulceration, crypt abscesses, lymphoid aggregates, and architectural distortion, we deﬁned
surgical resections from CD patients as microscopic unaffected ileum and inﬂamed ileum (Figure 2(a)). We observed
a signiﬁcantly increased level of stat3 mRNA expression in

the inﬂamed ileums, compared to unaﬀected ileum of CD
patients (Figure 2(b)), suggesting STAT3 activity was upregulated under inﬂammation. In addition, the stat3 expression
level was also increased in the peripheral blood of CD
patients, compared to healthy donors (Supplementary
Figure 1). Furthermore, an altered expression pattern of
inﬂammatory genes was observed in the inﬂamed ileum of
CD patients, compared to unaﬀected ileum (Figure 2(c), A).
Among those inﬂammatory genes, we further evaluated the
STAT3-related genes, such as Il-17a, tnf, and Il-10, and
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pSTAT3 positive cells per HPF

60
Unaffected ileum

Inflamed ileum

40

20

0
Unaffected ileum
(a)

Inflamed ileum

(b)

Figure 3: Increased activation of STAT3 signaling in the inﬂamed ileum of Crohn’s disease patients. (a) Representative images of pSTAT3Y705 IHC staining on unaﬀected (n = 6) and inﬂamed ileum of CD patients (n = 10). pSTAT3+ cells were shown as brown dots. Images were
obtained under 20x magniﬁcation. Scale bar = 50 μm. (b) Statistical analysis of pSTAT3-Y705+ cells per HPF in unaﬀected and inﬂamed ileum
of CD patients. Unpaired Mann-Whitney t test was performed, α = 0 05.

found increased expression levels of those STAT3 target
genes in inﬂamed ileum tissues (Figure 2(c), B). The
evaluated gene IDs were listed in Supplementary Table 2,
and the calculated expression levels of each gene were
reported in Supplementary Table 3. In order to investigate
whether STAT3 rs744166 associates with the increase of
STAT3-related gene expression during inﬂammation, we
then genotyped these patients. As the result, the genotype
of sample 1, 2, and 5 was A/A, and the genotype of sample
6 was GG. Samples 3 and 4 were the same individual before
and after treatment of 5-month Ustekinumab (anti-IL12/23
p40 antibody), and this patient was a heterozygous “A”
carrier. However, the data implied this increased
proinﬂammatory gene expression level was not associated
with STAT3 rs744166 risk allele “A” but correlated with the
inﬂammation level.
3.3. Increased Activation of STAT3 Signaling in the Inﬂamed
Ileum of Crohn’s Disease Patients. To examine the activation
of STAT3 signaling, we performed IHC staining of pSTAT3Y705 on paraﬃn-embedded tissue sections of CD patients.
The phosphorylated STAT3 signal was detected mainly in
those immune cells located in the lamina propria, as well as
intestinal epithelial cells for tissue repair in the inﬂamed
ileum [28] (Figure 3(a)). pSTAT3+ cells were counted per
high-power ﬁeld (HPF) in unaﬀected tissues and inﬂamed
tissues of CD patients, and an increased activation of STAT3
was observed in the inﬂamed ileum (Figure 3(b)).
3.4. Activation of STAT3 Signaling in Innate Lymphoid Cells.
STAT3 has been shown that plays a critical role in Th17
development and function, responding to IL-6 and IL-23 signals. As the innate compartment of T helper cells, ILCs also
respond to IL-23 stimulation, and the activation of STAT3
was crucial to the IL-22 production of ILC3s [22]. However,
it is unknown whether STAT3 involves in ILC1-to-ILC3
transdiﬀerentiation as IL-23 is the driving cytokine for this
plasticity [15]. We have observed diﬀerential frequency of
Lineage−CRTH2−CD45+NKp44−CD117−CD127+ILC subset
in the inﬂamed terminal ileum of CD patients [13], suggest-

ing there was a dysregulated ILC plasticity in CD patients.
Herein, we evaluated pSTAT3 levels in ILC subsets in
response to IL-23 stimulation using PBMCs from healthy
donor, and we also desired to investigate whether the carriage
of STAT3 rs744166 “A” allele correlates with the altered activation level of STAT3 in ILCs. As the result, the NCR-ILC3s
(Lin-CD45+CD56-CD127+CRTH2-CD117+NKp44cells)
responded rapidly to IL-23 stimulation (Figure 4(a)), and
these cells are more progenitor-like cells which are able to
diﬀerentiate to NCR+ILC3s [29]. We then examined the
phosphorylation level of STAT3 following IL-23 in each
ILC subset (Figure 4(b)). To our surprise, the pSTAT3 signal
was also detected in the Lin-CD45+CD56+CD127+CRTH2-CD117-NKp44- ILC1s, which were reported accumulated in the inﬂamed ileum of CD patients [13]. This
result suggested that the activation of STAT3 signaling
may be the ﬁrst step of a signaling cascade for ILC1-toILC3 plasticity and implied that STAT3 potentially has a
regulatory role for ILC1 functioning. Furthermore, we
eager to investigate whether the STAT3 genotypic variant
has impact on cellular STAT3 activation in ILCs in
response to IL-23. Here, we used PBMCs from donors
with A/A and G/G genotypes to evaluate the potential
eﬀect of STAT3 “A” risk allele carriage on the phosphorylation of STAT3 in ILCs. Notably, the result revealed that
donors carrying STAT3 rs744166 “A” risk allele exhibited a
higher basal level of STAT3 tyrosine phosphorylation as
well as an increased IL-23-stimulated pSTAT3 level in
Lin-CD45+CD56+CD127+CRTH2- ILCs (Figure 4(c), A:
A/A donor; B: G/G donor). By examination of pSTAT3
after 15 mins and 2 hrs of IL-23 stimulation, we illustrated
that there was no delayed dephosphorylation of STAT3 in
ILCs. In addition, the carriage of “A” allele did not impact
the dephosphorylation of STAT3.

4. Discussion
Despite the introduction of numerous biological agents,
including anti-TNFs, anti-integrin blockers, and more
recently, anti-IL12/23 drugs, for Crohn’s disease patients in
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Lin–CD45+CD56–CD127+CRTH2–
0

1.27

1.27

64.9

32.6

NKp44

0

97.5

2.49

CD117
(a)

NKp44−CD117−ILC1s

NKp44−CD117+ILC3s

Unstained control

0.93

0.93

With IL-23

70.1

70.0

Without IL-23

10.2

25.9

pSTAT3

pSTAT3
(b)

A/A

G/G

Stimulated with
IL-23 (15 mins)

65.2%

Stimulated with
IL-23 (15 mins)

43.8%

Stimulated with
IL-23 (2 hrs)

3.7%

Stimulated with
IL-23 (2 hrs)

3.1%

Unstimulated

46.4%

Unstimulated

14.5%

pSTAT3

pSTAT3

(A)

(B)
(c)

Figure 4: Activation of STAT3 signaling in innate lymphoid cells in response to IL-23 stimulation. (a) PBMCs from healthy donor were
stimulated by 20 ng/ml of IL-23 for 15 minutes. After gating Lin-CD45+CD127+CRTH2- cells, the ILC population was further gated based
on CD117 and NKp44 expression. The CD117+NKp44- ILC3 population (NCR-ILC3 phenotype) was induced by IL-23 stimulation. (b)
IL-23 activated STAT3 signaling in both the CD117-NKp44- ILC1 and CD117+NKp44- ILC3 subsets. (c) After gating
Lin-CD45+CD56+CD127+CRTH2- ILCs, the tyrosine phosphorylation level of STAT3 was evaluated in ILCs. Donor with A/A genotype
was shown in (A), and donor with G/G genotype was demonstrated in (B). The pSTAT3 level after 15 mins or 2 hrs stimulation of IL-23
indicated there was no delayed dephosphorylation in donors, suggesting risky allele “A” carriage does not aﬀect the dephosphorylation of
STAT3 in ILCs.
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remission, relapse rates at one, two, ﬁve, and ten years are
estimated at 20%, 40%, 67%, and 76%, respectively [30].
Therefore, a better understanding of CD pathogenesis is
needed in order to select more speciﬁc and eﬀective treatment regimens. There are several newly approved small molecule inhibitors targeting JAK-STAT signaling; however, the
responsiveness varies by individual [31]. This study was
mainly focused on investigating the role of STAT3 in the
pathogenesis and progression of Crohn’s disease. We
positively correlated the prevalence of the STAT3 rs744166
risky allele “A” with disease severity in terms of surgery numbers (Figure 1). In addition, we observed an increased level of
stat3 mRNA, STAT3-related gene expression, as well as activation of STAT3 signaling (phosphorylated STAT3) in
inﬂamed ileum tissues of CD patients compared to unaffected ileum (Figures 2 and 3). To investigate STAT3
activity in the innate lymphoid cells of particular interest,
we then speciﬁcally examined pSTAT3 in each of the
ILC subsets in response to IL-23 stimulation (Figure 4).
Notably, we found that STAT3 signaling was not only
activated in the NCR-ILC3 subset but also activated in
Lin-CD45+CRTH2-CD127+CD117-NKp44- cells. Moreover,
we illustrated the carriage of STAT3 genotypic variant
results in an increased basal and IL-23-stimulated STAT3
tyrosine phosphorylation, but it does not aﬀect the
dephosphorylation of STAT3 in ILCs.
Previous studies have focused largely on the role of
adaptive immunity and how it drives the pathogenesis as well
as progression of Crohn’s disease. The research on innate
immune responses have been continuously expanded over
the past two decades [32]. As the important tissue-resident
guardian, innate lymphoid cell has been investigated in both
steady state and diseased state, suggesting the important role
of ILCs in mucosal immunity [33]. Speciﬁcally in Crohn’s
disease patients, our previously published study showed that
the accumulation of IFN-γ-producing Lin-CD45+CRTH2-CD127+CD117-NKp44- cells in the inﬂamed terminal ileum of CD patients correlates with disease severity
[13]. However, the paradox we have observed is an increased
STAT3 activity along with decreased ILC3 numbers in the
inﬂamed tissues of CD patients. Bernink et al. not only
proposed that IL-23 triggered ILC1-to-ILC3 transdiﬀerentiation but also pointed out that sustained exposure of
IL-23 was able to promote the reverse conversion [15].
Other groups also pointed out that IL-23 responsive ILC3s
induced pathogenesis of neonatal intestinal inﬂammation
[34]. Additionally, it has been shown that STAT3
phosphorylation in ILC3s was suppressed by the presence
of Treg and Th17 cells [35]. In this study, we revealed that
the STAT3 genotypic variant rs744166 risk allele “A” was
associated with increased basal and IL-23 triggered the
pSTAT3 level in ILCs, but there was no impact on the
dephosphorylation of STAT3 in those genetically susceptible
individuals. Taken together, we suggested that investigation
of STAT3 signaling in a cell-speciﬁc manner is needed for
future researches. IL-23-induced activation of STAT3
signaling in CD117-NKp44- ILC subset suggested that STAT3
plays a role in the initiation of ILC plasticity and also potentially involves in regulating Lin-CD45+CRTH2-CD127+-

Journal of Immunology Research
CD117-NKp44- ILC1 function. More in depth investigation
on exact gene regulation of STAT3 in ILCs is necessary to further explore the exact molecular mechanism of ILC plasticity
and heterogeneity property.

5. Conclusion
Overall, this study illustrated that increased STAT3 activity
was associated with the pathogenesis and progression of
Crohn’s disease. Particularly, activated STAT3 signaling in
IL-23 responsive ILCs may lead to the chronic relapse of
CD. Notably, individuals carrying STAT3 rs744166 “A” risk
allele exhibited increased basal and IL-23-stimulated STAT3
tyrosine phosphorylation in the peripheral ILCs. The results
provide a novel concept of a potential mechanism of ILC
plasticity and also contribute to potential mechanistic strategies for use in personalized medicine in the treatment of
Crohn’s disease patients.
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